SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

FDA approval provides an important option for those unable to take oral formulation of TPOXX

Shares are moving higher today by 30% in the pre-market on FDA approval of IV TPOXX  for the treatment of small pox.

Shares are trading around $9.50 as I’m wiring this on more than 15,000 trades and 2.3 million plus shares and climbing.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.